Compare Ascendis Pharma A/S (ASND) vs EOG Resources Inc (EOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs EOG Resources Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while EOG Resources Inc trades at $136.24 (market cap $71.43B). The key difference: EOG Resources Inc is far larger — about 4× Ascendis Pharma A/S's market cap, and EOG Resources Inc pays a 3.04% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | EOG | |
|---|---|---|
Market Cap | $17.74B | $71.43B |
Sector | Health | Energy |
52-Week High | $277.18 | $149.89 |
52-Week Low | $163.32 | $101.78 |
Enterprise Value | $18.11B | $75.88B |
Dividend Yield | — | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EOG Resources trades at $134.10, up 0.42% with a bullish technical outlook and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.41 exceeding expectations. Valuation metrics appear attractive with a P/E of 13.19 and EV/EBITDA of 6.36. Recent news highlights operational excellence and shareholder returns, including $8.5 billion in projected 2026 free cash flow. Technical indicators show support at $132 and resistance at $136.
Outlook remains positive driven by oil price strength and efficient operations, though risks include commodity volatility and capital expenditure pressures. Analyst consensus is strongly bullish with a $156.40 price target, representing 16.6% upside. The absence of sell ratings underscores confidence in EOG's financial health and strategic positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
